Yatin Suneja
Stock Analyst at Guggenheim
(3.55)
# 900
Out of 4,915 analysts
138
Total ratings
51.24%
Success rate
4.61%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Buy | $50 → $101 | $70.84 | +42.58% | 2 | Jul 23, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Buy | $26 | $3.57 | +628.29% | 6 | Jun 25, 2025 | |
| ALMS Alumis | Reinstates: Buy | $18 | $4.10 | +339.02% | 2 | Jun 10, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $54 → $90 | $24.98 | +260.29% | 13 | May 28, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $23 → $25 | $1.56 | +1,502.56% | 5 | May 16, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,100 → $1,065 | $598.89 | +77.83% | 11 | May 9, 2025 | |
| GHRS GH Research | Maintains: Buy | $32 → $29 | $13.98 | +107.44% | 1 | May 9, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $155 → $165 | $136.76 | +20.65% | 5 | May 6, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $18 → $12 | $8.71 | +37.77% | 4 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $810 | $554.58 | +46.06% | 6 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.44 | +941.67% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $0.88 | +1,036.36% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.70 | +894.32% | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $16.62 | - | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $20.82 | +303.46% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $15.75 | +185.71% | 3 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.08 | - | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $8.05 | - | 3 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $45 | $9.23 | +387.54% | 3 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $23.53 | -15.00% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.06 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $23.34 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $65 | $17.29 | +275.94% | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $155 → $170 | $56.59 | +200.41% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.54 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $22.81 | +294.65% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $101.26 | +23.44% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $11.40 | +40.35% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $50.46 | +52.60% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $30.77 | +59.25% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $9.84 | +458.94% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $126.64 | +176.37% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.68 | - | 5 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.64 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $13.71 | +75.05% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $105.14 | -67.66% | 2 | Jan 14, 2020 |
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Buy
Price Target: $50 → $101
Current: $70.84
Upside: +42.58%
Larimar Therapeutics
Jun 25, 2025
Reiterates: Buy
Price Target: $26
Current: $3.57
Upside: +628.29%
Alumis
Jun 10, 2025
Reinstates: Buy
Price Target: $18
Current: $4.10
Upside: +339.02%
AnaptysBio
May 28, 2025
Maintains: Buy
Price Target: $54 → $90
Current: $24.98
Upside: +260.29%
Cabaletta Bio
May 16, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $1.56
Upside: +1,502.56%
argenx SE
May 9, 2025
Maintains: Buy
Price Target: $1,100 → $1,065
Current: $598.89
Upside: +77.83%
GH Research
May 9, 2025
Maintains: Buy
Price Target: $32 → $29
Current: $13.98
Upside: +107.44%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $155 → $165
Current: $136.76
Upside: +20.65%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $18 → $12
Current: $8.71
Upside: +37.77%
Regeneron Pharmaceuticals
May 1, 2025
Maintains: Buy
Price Target: $940 → $810
Current: $554.58
Upside: +46.06%
Mar 26, 2025
Reiterates: Buy
Price Target: $15
Current: $1.44
Upside: +941.67%
Mar 26, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $0.88
Upside: +1,036.36%
Mar 21, 2025
Reiterates: Buy
Price Target: $7
Current: $0.70
Upside: +894.32%
Mar 20, 2025
Reiterates: Buy
Price Target: n/a
Current: $16.62
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $84
Current: $20.82
Upside: +303.46%
Mar 12, 2025
Reiterates: Buy
Price Target: $45
Current: $15.75
Upside: +185.71%
Mar 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.08
Upside: -
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $8.05
Upside: -
Jan 3, 2025
Upgrades: Buy
Price Target: $45
Current: $9.23
Upside: +387.54%
Jan 3, 2025
Downgrades: Neutral
Price Target: $20
Current: $23.53
Upside: -15.00%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.06
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $23.34
Upside: -
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $17.29
Upside: +275.94%
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $56.59
Upside: +200.41%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.54
Upside: -
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $22.81
Upside: +294.65%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $101.26
Upside: +23.44%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $11.40
Upside: +40.35%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $50.46
Upside: +52.60%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $30.77
Upside: +59.25%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $9.84
Upside: +458.94%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $126.64
Upside: +176.37%
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $8.68
Upside: -
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.64
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $13.71
Upside: +75.05%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $105.14
Upside: -67.66%